 A variety of approaches have been used to target c-Met, each focusing on one of the serial steps that regulate c-Met activation by antibodies, peptide agonists, decoy receptors and other biologic inhibitors
or small molecules inhibitors.The c-Met RTK subfamily is different in structure to many other RTK families